Safety and Immunogenicity of a Chlamydia Vaccine CTH522

Inclusion Criteria: IC1: Healthy males and females between 18-45 years old on the day of the first vaccination. IC2: Has been properly informed about the trial and signed the consent form. IC3: Is willing and likely to comply with trial procedures. IC4: Is prepared to grant authorised persons access to his/her trial-related medical record. IC5: Is willing to use acceptable contraceptive measures during the trial (two weeks before and two weeks after the trial). Heterosexually active female capable of becoming pregnant must agree to use hormonal contraception, intrauterine device, intrauterine hormone releasing system, or to complete abstinence from at least two weeks before the first vaccination until at least two weeks after the last. Complete abstinence (defined as refraining from heterosexual intercourse) must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods), withdrawal and progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, are not acceptable methods of contraception. Exclusion criteria: EX1: Is positive for C. trachomatis via urine PCR or has a known history of C. trachomatis. EX2: Is positive for gonorrhoea via urine PCR test, or HIV, hepatitis B/C, syphilis via blood tests. EX3: Has a significant active disease such as cardiac, liver, immunological, neurological, psychiatric, or clinically significant…